What we're see­ing at JPM so far: Up­com­ing BD moves, pipeline up­dates and more

SAN FRAN­CIS­CO — Af­ter two years of Covid-stalled vir­tu­al deal­mak­ing, the JP Mor­gan Health­care Con­fer­ence re­turned as an in-per­son event on Mon­day, with plen­ty of ex­cite­ment in the air.

At­ten­dees crammed in­to the West­in St. Fran­cis, clog­ging the hall­ways with few masks on faces, to lis­ten to phar­ma and biotech ex­ecs of­fer their lat­est pos­i­tive news and ex­pec­ta­tions for 2023. Bris­tol My­ers Squibb and Bio­gen drew stand­ing room on­ly crowds but of­fered few new up­dates. Pro­test­ers chant­ed briefly out­side the ho­tel ac­cus­ing Gilead of price-goug­ing their HIV drugs and left by lunchtime. The line for free lunch stretched hun­dreds of peo­ple long, wrap­ping around the con­fer­ence rooms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER